Heterocyclic Compounds

Publication Title: 
Journal of Chemical Information and Modeling

We report the development and implementation of a cheminformatics tool which aids in the design of compounds during exploratory chemistry and lead optimization. The Heterocyclic Regioisomer Enumeration and MDDR Search (HREMS) tool allows medicinal chemists to build greater structural diversity into their synthetic planning by enabling a systematic, automated enumeration of heterocyclic regioisomers of target structures.

Tyagarajan, Sriram
Lowden, Christopher T.
Peng, Zhengwei
Dykstra, Kevin D.
Sherer, Edward C.
Krska, Shane W.
Publication Title: 
Molecules (Basel, Switzerland)

Isoxazoline analogues of artemisinin were obtained in low yield and low diastereoselectivity from the 1,3-dipolar cycloaddition of nitrile oxides. Alternatively, starting from the aldehyde 7, a number of transformations--Wittig reaction and reduction, Henry reaction and cyanohydrin formation--were achieved in significantly higher yields. In the cases where a new stereocenter was introduced this occurred diastereoselectively.

Van Neck, Tine
Van Mierloo, Sarah
Dehaen, Wim
Publication Title: 
Antimicrobial Agents and Chemotherapy

In an attempt to augment the efficacy of 7-chloro 4-aminoquinoline analogs and also to overcome resistance to antimalarial agents, we synthesized three cyclen (1,4,7,10-tetraazacyclododecane) analogs of chloroquine [a bisquinoline derivative, 7-chloro-4-(1,4,7,10-tetraaza-cyclododec-1-yl)-quinoline HBr, and a 7-chloro-4-(1,4,7,10-tetraaza-cyclododec-1-yl)-quinoline-Zn(2+) complex]. The bisquinoline displays the most potent in vitro and in vivo antimalarial activities.

Khan, M. O. Faruk
Levi, Mark S.
Tekwani, Babu L.
Khan, Shabana I.
Kimura, Eiichi
Borne, Ronald F.
Publication Title: 
Journal of Medicinal Chemistry

In only five simple steps and 48% overall yield from the natural trioxane artemisinin, the thermally and hydrolytically stable trioxane fluoroanilide 4b has been prepared. Upon one oral dose of only 6.8 mg/kg of monomeric trioxane 4b combined with 20 mg/kg of mefloquine hydrochloride, all of the malaria-infected mice lived until at least day 30 post infection. Of the five mice in this surviving group, four (80%) were completely cured (no parasites in their blood) and one mouse had 4% blood parasitemia.

Woodard, Lauren E.
Chang, Wonsuk
Chen, Xiaochun
Liu, Jun O.
Shapiro, Theresa A.
Posner, Gary H.
Publication Title: 
Antimicrobial Agents and Chemotherapy

We report the in vitro activities of trioxaquines against larval and adult-stage schistosomes at 5 and 50 microg/ml, respectively. Such activities are equivalent to that of praziquantel, the major and rather unique drug currently used for the treatment of schistosomiasis. In this range of concentrations, artemisinin derivatives (artesunate and artemether) have no activity.

Boissier, Jérôme
Coslédan, Frédéric
Robert, Anne
Meunier, Bernard
Publication Title: 
Bioorganic & Medicinal Chemistry Letters

Four 5-carbon-linked trioxane dimer orthoesters (6a-6d) have been prepared in 4 or 5 chemical steps from the natural trioxane artemisinin (1). When administered orally to malaria-infected mice using a single dose of only 6 mg/kg body weight along with 18 mg/kg of mefloquine hydrochloride, trioxane dimer orthoester sulfone 6d completely and safely cured the mice; after 30 days, the cured mice showed no detectable parasitemia, gained at least as much weight as the control mice (no infection), and behaved normally.

Moon, Deuk Kyu
Tripathi, Abhai
Sullivan, David
Siegler, Maxime A.
Parkin, Sean
Posner, Gary H.
Publication Title: 
Proceedings of the National Academy of Sciences of the United States of America

Ozonide OZ439 is a synthetic peroxide antimalarial drug candidate designed to provide a single-dose oral cure in humans. OZ439 has successfully completed Phase I clinical trials, where it was shown to be safe at doses up to 1,600 mg and is currently undergoing Phase IIa trials in malaria patients. Herein, we describe the discovery of OZ439 and the exceptional antimalarial and pharmacokinetic properties that led to its selection as a clinical drug development candidate.

Charman, Susan A.
Arbe-Barnes, Sarah
Bathurst, Ian C.
Brun, Reto
Campbell, Michael
Charman, William N.
Chiu, Francis C. K.
Chollet, Jacques
Craft, J. Carl
Creek, Darren J.
Dong, Yuxiang
Matile, Hugues
Maurer, Melanie
Morizzi, Julia
Nguyen, Tien
Papastogiannidis, Petros
Scheurer, Christian
Shackleford, David M.
Sriraghavan, Kamaraj
Stingelin, Lukas
Tang, Yuanqing
Urwyler, Heinrich
Wang, Xiaofang
White, Karen L.
Wittlin, Sergio
Zhou, Lin
Vennerstrom, Jonathan L.
Publication Title: 
Molecules (Basel, Switzerland)

Inonotus obliquus is a medicinal mushroom used in Russian and Eastern European folk medicine for the treatment of gastrointestinal cancer, cardiovascular disease and diabetes. Previous studies in our laboratory have demonstrated that the mycelium powders of I. obliquus possess significant antihyperglycemic effects in a mouse model of diabetic disease induced by alloxan. However, the active ingredients of mycelium powders responsible for the diabetes activity have not been identified. This study aims to identify the active ingredients of I.

Geng, Yan
Lu, Zhen-Ming
Huang, Wei
Xu, Hong-Yu
Shi, Jin-Song
Xu, Zheng-Hong
Subscribe to RSS - Heterocyclic Compounds